Hwasun Jeonnam National University Hospital Supports Domestic and International Pharmaceutical and Bio Companies in New Drug Development

Operating a Joint Booth at 'BIX2024'... Product Contracts and Investment Consultations

Aiming to Strengthen Competitiveness in High-Value New Drug Material Industry

Hwasun Chonnam National University Hospital has stepped up to support blockbuster-level new drug development and commercialization by domestic and international pharmaceutical and bio companies.

The aim is to strengthen the competitiveness of the new drug material industry, which is gaining attention for its high added value, through collaboration with pharmaceutical and bio companies.

The Advanced Precision Medicine Industrialization Support Center at Hwasun Chonnam National University Hospital recently announced on the 29th that it operated a joint booth with pharmaceutical and bio companies such as Shangri-La Bio, NPK, and K-Blue Bio at ‘BioPlus-Interphex Korea 2024 (BIX2024)’ held at COEX in Seoul, conducting product contracts and investment consultations.

‘BIX2024’ is an integrated business platform convention event covering the entire value chain of the domestic and international biopharmaceutical industry.

At this event, the Advanced Precision Medicine Industrialization Support Center focused on promoting the innovative new drug material substance commercialization non-clinical core demonstration support project to related companies in the pharmaceutical and bio industry, hospitals, and institutional officials.

They also held sessions introducing equipment utilization, non-clinical trials, clinical consulting, and corporate support programs.

Participating companies achieved results such as product contracts and over 150 distribution, investment, and collaboration consultations through joint booth operations.

Shangri-La Bio promoted ▲NKT cell anticancer immune cell therapy technology ▲cell therapy CDMO business ▲exosome cosmetics and exosome hair tonic products, achieving 116 investment and technical consultations with domestic and international companies and buyers. They also discussed the industrialization of anticancer immune cell therapy technology and exosome products with corporate and individual investors.

NPK Co., Ltd. exhibited and introduced health functional food raw materials and products such as their self-developed K-naksan bacteria and gluten-degrading enzymes, and through about 20 technical consultations, established collaborative relationships including discovering new clients and OEM/ODM production.

K-Blue Bio, which develops therapeutics and diagnostic devices for precision medicine targeting elderly and relapsed refractory hematologic cancers, showcased the ‘Hematologic Cancer NGS Panel’ product compliant with the 2022 World Health Organization (WHO) and International Consensus Classification (ICC) diagnostic and classification system guidelines, conducting 12 consultations with domestic hospitals, companies, and buyers.

Along with this, they achieved the establishment of a technology development collaboration network among companies for hematologic cancer genetic variation and target therapeutic selection using the NGS panel, as well as new drug development.

Shin Myung-geun, director of the Advanced Precision Medicine Industrialization Support Center and professor of laboratory medicine at Hwasun Chonnam National University Hospital, said, “To advance the high value-added new drug material industry ecosystem, we will collaborate with hospital infrastructure, domestic and international pharmaceutical and bio companies, and medical institutions. We will actively support the acceleration of blockbuster-level new drug development and diversification of applied products to contribute to strengthening the global competitiveness of the domestic pharmaceutical and bio industry.”

This content was produced with the assistance of AI translation services.